v3.24.1.1.u2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Operating expenses        
Research and development $ 3,660,642 $ 1,916,450 $ 9,763,333 $ 6,024,267
General and administrative 3,709,746 1,419,848 8,872,684 4,000,544
Total operating expenses 7,370,388 3,336,298 18,636,017 10,024,811
Loss from operations (7,370,388) (3,336,298) (18,636,017) (10,024,811)
Other income (loss)        
Change in fair value of simple agreement for future equity (16,793,000) (1,373,000) (13,717,000)  
Interest income 141,303 325 180,360 920
Total other loss (16,651,697) (1,372,675) (13,536,640) 920
Loss before income taxes (24,022,085) (4,708,973) (32,172,657) (10,023,891)
Net loss $ (24,022,085) $ (4,708,973) $ (32,172,657) $ (10,023,891)
Basic net loss per common share (in dollars per share) $ (4.79) $ (0.99) $ (6.73) $ (2.16)
Diluted net loss per common share (in dollars per share) $ (4.79) $ (0.99) $ (6.73) $ (2.16)
Weighted average number of common shares outstanding - basic (in shares) 5,014,604 4,771,025 4,778,685 4,638,505
Weighted average number of common shares outstanding - diluted (in shares) 5,014,604 4,771,025 4,778,685 4,638,505